NVCT

Nuvectis Pharma, Inc.

8.22 USD

Last updated Dec 9, 15:03 UTC

Yesterday HIGH

$8.5

Yesterday LOW

$8.02

52w HIGH

$18.65

52w LOW

$7.14

EPS

-0.37

PE

-22.22

Next Earnings

Mar 5, 2024

Overview News Government Trades

Nuvectis Pharma, Inc. stock is down -0.12% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 1 December’s closed higher than November.

Nuvectis Pharma focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

Benzinga Insights

Wed May 10, 2023

Nuvectis Pharma: Q1 Earnings Insights
Benzinga Newsdesk

Wed May 10, 2023

Nuvectis Pharma Q1 EPS $(0.27) Beats $(0.44) Estimate; Cash Balance Of $15.5M Will Be Sufficient To Meet Its Operating Expense Requirements Into 2H Of 2024

Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.44) by 38.64 percent. This is a 15.62 percent increase over losses of $(0.32) per share from
Benzinga Newsdesk

Mon Apr 10, 2023

Nuvectis Pharma Initiates Phase 1b Study For NXP800 In Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
Benzinga Newsdesk

Fri Mar 17, 2023

Nuvectis Pharma Announces Upcoming Presentations For NXP800 & NXP900 At Upcoming 2023 American Association For Cancer Research Meeting
Benzinga Newsdesk

Tue Mar 7, 2023

HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $21 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $21 price target.
Benzinga Newsdesk

Tue Mar 7, 2023

Nuvectis Pharma FY22 EPS $(1.51)
Benzinga Newsdesk

Fri Feb 10, 2023

HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $21 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $21 price target.
Happy Mohamed

Thu Feb 9, 2023

Nuvectis Pharma Announces A Publication In The Journal Of Experimental Medicine For NXP900 In An In-Vivo Model Of Metastatic Castration Resistant Prostate Cancer With Acquired Resistance To Enzalutamide, The Active Ingredient In Xtandi

Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious
Benzinga Newsdesk

Wed Jan 4, 2023

Nuvectis Pharma Announces Collaboration With ENGOT And GOG Foundation To Conduct The NXP800 Phase 1b Clinical Trial In ARID1A-Mutated Ovarian Carcinoma In Europe And In The U.S.

Dr. Susana Banerjee (The Royal Marsden NHS Foundation Trust, UK), will be the ENGOT and Global Clinical Trial Lead Dr. Shannon Westin (MD Anderson Cancer Center, Houston, TX) and Dr. Ramez Eskander (University of
Benzinga Newsdesk

Thu Dec 1, 2022

FDA Grants Fast Track Designation To Nuvectis Pharma's NXP800 For Treatment Of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

Nuvectis Pharma, Inc (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of

ALXO $12.31 USD

IYW $118.24 USD

BITW BITW $0.00 USD

RVLV $15.48 USD

TECS $10.99 USD

SRUUF SRUUF $0.00 USD

EXTR $17.02 USD

AMBC $16.40 USD